| 2024-11-19 | -0.2 % |
|
| 2024-11-14 | -0.61 % |
|
| 2024-11-11 | +0.18 % |
|
| 2024-11-04 | -0.8 % |
|
| 2024-11-01 | +4.61 % |
|
| 2024-10-31 | -0.94 % |
|
| 2024-10-28 | -0.13 % |
|
| 2024-10-24 | -0.4 % |
|
| 2024-10-23 | +0.77 % |
|
| 2024-10-22 | -0.74 % |
|
| 2024-10-21 | -2.01 % |
|
| 2024-10-18 | +1.27 % |
|
| 2024-10-17 | +0.06 % |
|
| 2024-10-16 | +1.53 % |
|
| 2024-10-15 | -1.02 % |
|
| 2024-10-14 | +0.97 % |
|
| 2024-10-11 | +0.43 % |
|
| 2024-10-10 | -0.28 % |
|
| 2024-10-09 | +1.15 % |
|
| 2024-10-08 | +1.12 % |
|
| 2024-10-07 | +0.64 % |
|
| 2024-10-04 | +0.37 % |
|
| 2024-10-02 | +0.07 % |
|
| 2024-10-01 | -0.39 % |
|
| 2024-09-30 | +1.41 % |
|
| 2024-09-27 | -0.27 % |
|
| 2024-09-26 | +0.11 % |
|
| 2024-09-25 | -0.64 % |
|
| 2024-09-24 | -1.28 % |
|
| 2024-09-23 | +0.98 % |
|
| 2024-09-16 | +1.06 % |
- Abbott Laboratories (ABT) stock rose 1.06% recently, likely due to positive investor sentiment buoyed by its strong dividend growth potential, especially in contrast to its spinoff, AbbVie, which has consistently increased its dividends since 2013.
- The article discusses significant insider buy and sell transactions of US stocks, including Abbott Laboratories (ABT), which experienced a 1.06% increase, potentially influenced by the stock's market dynamics following the share sale by its CEO, as insider activities can affect investor sentiment and confidence.
Abbott Laboratories (ABT) stock may have gone up due to overall positive market reactions to recent trading activity, despite the CEO's substantial sale, which could have been seen as a routine transaction rather than a lack of confidence in the company's prospects.
- Abbott Laboratories (ABT) saw a 1.06% increase in stock value, likely due to positive investor sentiment surrounding its strategic growth potential and the performance of its next-generation drugs, despite challenges faced by its spinoff, AbbVie, following the patent expiration of Humira.
|
| 2024-09-13 | -0.37 % |
|
| 2024-09-06 | +0.67 % |
|
| 2024-09-05 | -1.14 % |
|
| 2024-08-15 | +0.96 % |
|
| 2024-08-13 | +0.41 % |
|
| 2024-07-22 | +1.66 % |
|
| 2024-07-19 | +1.96 % |
- Abbott Laboratories (ABT) stock was up 1.96% last night due to strong trading volume, positive earnings reports, and analysts' optimistic outlook, as the healthcare product maker reported higher than expected earnings and a growth in revenue for the quarter, resulting in a consensus price target of $120.18 along with buy ratings from multiple analysts.
- Summary: Abbott Laboratories (ABT) stock was up 1.96% following the company's earnings report, which revealed higher-than-expected earnings per share and revenue, with a year-over-year revenue increase of 4.0%. Analysts have given the stock positive ratings, with an average target price of $120.18, attributing the stock's rise to strong financial performance and positive analyst outlook.
Reason for stock increase: Abbott Laboratories stock increased due to the company surpassing earnings per share expectations, reporting strong revenue growth, and receiving positive ratings from analysts.
|
| 2024-07-18 | -4.4 % |
|
| 2024-07-12 | +0.04 % |
|
| 2024-07-11 | +1.1 % |
|
| 2024-07-08 | -1.83 % |
|
| 2024-07-03 | -0.84 % |
- The article discusses how Abbott Laboratories (ABT) had its target price adjusted by Evercore ISI and several other analysts, with a current consensus rating of Moderate Buy and a target price of $120.18. The stock of Abbott Laboratories went down by -0.84% due to Evercore ISI lowering its target price, along with other firms following suit, which affected the stock price negatively.
- The article mentions that Plimoth Trust Co. LLC reduced its position in Abbott Laboratories (ABT) stock by 0.8%, leading to a 0.84% decrease in the stock value, and the stock could have gone down due to various institutional investors and hedge funds making changes to their positions in the company, as well as company executives selling shares.
- SeaCrest Wealth Management LLC reduced its stake in Abbott Laboratories (NYSE: ABT) by 8.2%, leading to a -0.84% decrease in the company's stock, with several large investors making similar moves, and analysts providing varying recommendations, resulting in a consensus target price of $120.18, as highlighted in the article. The stock went down due to institutional investors reducing their stakes in Abbott Laboratories.
|
| 2024-07-02 | |
|
| 2024-07-01 | -0.68 % |
|
| 2024-06-28 | -0.71 % |
|
| 2024-06-27 | -0.22 % |
|
| 2024-06-25 | +0.18 % |
|
| 2024-06-21 | -0.8 % |
|
| 2024-06-20 | +2.48 % |
- The article reports that Abbott Laboratories stock (ABT) was up by 2.48% last night, and the stock's rise can be attributed to various hedge funds and institutional investors increasing their holdings in the company, as well as positive quarterly earnings results exceeding analyst expectations.
- The article discusses Abbott Laboratories (ABT) stock, highlighting its increase of 2.48% last night and its position as the 5th best dividend king for safe dividend growth due to its consistent dividend increases and the company's positive outlook in rapidly expanding healthcare markets. The stock goes up due to being part of the healthcare sector, which is considered defensive, and its strong performance in various healthcare areas like diabetes management, diagnostics, cardiovascular care, and nutrition. Additionally, analyst predictions and increased positions by firms like Polen Capital contribute to the positive outlook for Abbott Laboratories.
- Summary: Abbott Laboratories (ABT) stock went up by 2.48% following Mather Group LLC cutting its stake by 33.8% and other institutional investors adjusting their positions, while recent quarterly earnings reported a beat on earnings per share.
Reason for Stock Increase: The stock price of Abbott Laboratories (ABT) went up as Mather Group LLC and other institutional investors adjusted their stakes, possibly indicating confidence in the company's future performance. Additionally, the company reported better-than-expected earnings per share for the last quarter.
|
| 2024-06-18 | +0.52 % |
- Summary: Congress Asset Management Co. MA decreased its stake in Abbott Laboratories (ABT) stock, while other hedge funds have been buying shares; various brokerages have issued positive ratings and price targets on the stock, and recent insider selling has been disclosed, contributing to the stock's 0.52% increase.
Reason for ABT stock increase: The increase in ABT stock can be attributed to positive ratings and price targets from brokerages, new positions taken by hedge funds and institutional investors, strong earnings report exceeding analysts' expectations, upcoming quarterly dividend announcement, and certain corporate insiders selling shares.
- Livelsberger Financial Advisory recently purchased a new position in Abbott Laboratories (ABT) stock, contributing to a 0.52% increase in its value. The stock likely went up due to the continued interest and investments made by institutional investors, as well as positive quarterly earnings results indicating growth and financial stability.
- The article discusses Abbott Laboratories (ABT) stock, which was up 0.52% last night; the stock went up due to institutional investors modifying their holdings, such as B. Riley Wealth Advisors Inc. decreasing its position, and positive quarterly earnings data that beat analysts' estimates.
|
| 2024-06-17 | -0.22 % |
|
| 2024-06-14 | +0.22 % |
|
| 2024-06-13 | -0.89 % |
- Abbott Laboratories (ABT) stock was down -0.89% last night, and the article discusses the company's commitment to diversity, equity, and inclusion as key to their success, emphasizing the importance of fostering a diverse and inclusive workplace for their employees' well-being and professional growth. The stock likely went down due to various factors impacting the financial markets or the healthcare industry, rather than directly related to the company's diversity efforts.
- The article discusses Abbott Laboratories (ABT) stock being down by -0.89% last night, and summarizes the company's commitment to diversity, equity, and inclusion in the workplace, focusing on the importance of fostering a diverse and inclusive environment to drive success and better serve their purpose. The stock likely went down due to various factors such as market conditions, economic trends, competition, government regulations, or company-specific news.
|
| 2024-06-12 | -2.89 % |
|
| 2024-06-11 | -1.56 % |
|
| 2024-06-10 | -0.08 % |
- Abbott Laboratories' stock went down due to the last night's -0.08% dip, which coincided with the company receiving FDA clearance for two new over-the-counter continuous glucose monitoring systems, Lingo™ and Libre Rio™, designed to aid individuals in tracking their glucose levels and making health improvements, thus reflecting Abbott's commitment to innovation in the healthcare industry.
- The article discusses a recent decision by the Irish Tax Appeals Commission concerning the transfer pricing treatment of employee stock options issued by a foreign parent company to its Irish subsidiary. The decision, which was flawed according to the article, led to Abbott Laboratories (ABT) stock going down by -0.08%. The stock may have been negatively impacted due to concerns arising from the transfer pricing treatment of employee stock options not being in favor of the company, potentially affecting its financial standing and investor confidence.
- Abbott Laboratories' stock (ABT) went down by -0.08% after they received FDA clearance for their two new continuous glucose monitoring systems, Lingo and Libre Rio, which are aimed at catering to specific consumer needs in glucose monitoring. The slight decline in the stock price could be attributed to the reduction in price target by Barclays, despite maintaining an Overweight rating, and overall market conditions.
|
| 2024-06-07 | +3.17 % |
|
| 2024-06-06 | +1.01 % |
- The article discusses a technical glitch that temporarily affected certain stocks, including Abbott Laboratories (ABT), on the New York Stock Exchange, leading to trading halts and inaccurate price movements; however, the issue was resolved shortly after. The upward movement in Abbott Laboratories stock may be attributed to the technical anomaly on the exchange impacting trading activities.
- Summary: Health care product maker Abbott Laboratories (ABT) stock was 1.01% up last night, with several large investors altering their positions and analysts issuing varied ratings on the stock recently.
Reason for stock increase: The stock likely saw an increase due to continued investor interest, positive earnings results, and institutional investments, as well as analyst coverage and ratings indicating buy recommendations.
(Note: The actual reasons for stock movements can be influenced by various factors, including company performance, market conditions, news, and investor sentiment.)
- Abbott Laboratories (ABT) stock went up by 1.01% following the announcement of the CE Mark approval for the AVEIR™ dual chamber (DR) leadless pacemaker system in Europe, which is a breakthrough technology designed to treat people with abnormal or slow heart rhythms by providing synchronized pacing between two leadless pacemakers.
|
| 2024-06-05 | -0.19 % |
|
| 2024-06-04 | +0.54 % |
|
| 2024-06-03 | +0.67 % |
|
| 2024-05-31 | +0.44 % |
|
| 2024-05-30 | +1 % |
|
| 2024-05-29 | -1.2 % |
|
| 2024-05-28 | -1.92 % |
- The article compares two small-cap medical companies, Mobile-health Network Solutions and Materialise, based on various financial metrics, with Materialise being favored by analysts due to its higher revenue, earnings, and potential upside. Abbott Laboratories (ABT) stock went down by -1.92% due to external factors such as market conditions, industry trends, or company-specific news that impacted investor sentiment.
- The article discusses Hilltop Holdings Inc.'s increased position in Abbott Laboratories (ABT) with several other institutional investors and hedge funds making changes to their positions in the company, while also mentioning recent insider selling activities. The stock of Abbott Laboratories went down by -1.92%, and this drop may be attributed to the increased selling by corporate insiders.
- Abbott Laboratories (ABT) stock was down by -1.92% last night, and the decrease might be attributed to various hedge funds and institutional investors increasing their stakes in ABT or analysts issuing reports with lower price targets, although the company continues to report strong earnings and revenue.
|
| 2024-05-23 | -0.56 % |
|
